One-Year Results of Treatment of Diabetic Macular Edema with Aflibercept Using the Treat-and-Extend Dosing Regimen: the VIBIM Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q3Scopus Q1
- 저널
- OPHTHALMOLOGICA243(4) · pp.255 · 2020
- 피인용
- Web of Science 25Scopus 24
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2019 1.926
- ISSN
- 0030-3755
저자
- Pak, Kang Yeun제1저자a Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
- Shin, Jae Pilb Department of Ophthalmology, Kyungpook National University School of Medicine, Deagu, Republic of Korea
- Kim, Hyun Woonga Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea
- Sagong, Minc Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Republic of Korea
- Kim, Yu Cheold Department of Ophthalmology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Republic of Korea
- Lee, Sang Joone Department of Ophthalmology, Kosin University College of Medicine, Busan, Republic of Korea
- Chung, In Youngf Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Republic of Korea
- 박성후g Department of Ophthalmology, Pusan National University, College of Medicine, Yangsan, Republic of Korea
- 이지은교신저자g Department of Ophthalmology, Pusan National University, College of Medicine, Yangsan, Republic of Korea
초록
Introduction: The purpose of this study was to report the one-year results of treatment of diabetic macular edema (DME) with aflibercept using a treat-and-extend regimen (TER). Methods: This was a prospective, multicenter, single-arm study planned for 2 years. The eyes received 5 consecutive intravitreal injections of 2 mg of aflibercept every 4 weeks, and the interval between injections was then adjusted by 2 weeks based on changes in the central subfield macular thickness (CSMT). If the CSMT was worse, stable, or better, the interval was shortened, extended, or maintained, respectively. The primary outcome measure was the change in best-corrected visual acuity (BCVA) from baseline to 104 weeks, and the secondary outcome was the change in BCVA from baseline to 52 weeks. Results: Of the 48 patients enrolled, 46 completed a 1-year visit. BCVA improved significantly by 9.1 letters (95% confidence interval: 5.3-13.0 letters) from 56.2 letters at baseline (p < 0.001), and CSMT decreased by -171.7 <mu>m from 489.4 to 317.7 mu m (p < 0.001). The proportion of eyes having 20/40 or better vision increased from 17.4 to 41.3%, and the proportion of eyes that gained <greater than or equal to>15 letters was 28.3%. The mean number of injections was 8.5 times for 52 weeks. Worsening of macular edema did not occur in 76.1% of eyes during the extension period, and the interval between injections was extended to 12 weeks in 73.9% of eyes at 52 weeks. Conclusions: The TER showed 1-year efficacy comparable to that of the fixed dosing regimen of pivotal trials, and its flexible dosing would prevent overtreatment.
키워드
AfliberceptDiabetic macular edemaTreat-and-extend regimenINTRAVITREAL AFLIBERCEPTRANDOMIZED-TRIALDEFERRED LASERVEGF-TRAPRANIBIZUMABBEVACIZUMABRETINOPATHYPROMPT
식별자
- Scopus EID
- 2-s2.0-85078003834
- WoS UID
- 000600997600002



로그인
연구물 목록으로